Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 9/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25308813 | 1.00 | POLQ (0.43) | POLQPDE5AABL1PDK2PDK4 | |
| SCHEMBL30526801 | 0.88 | ABL1 (0.39) | POLQABL1CNR2PTGDR2FASN | |
| SCHEMBL30526885 | 0.84 | POLQ (0.49) | POLQABL1KDM4EALDH1A1HPGD | |
| SCHEMBL25308883 | 0.84 | POLQ (0.49) | POLQABL1KDM4EALDH1A1HPGD | |
| SCHEMBL31167922 | 0.82 | POLQ (0.48) | POLQPDE5A | |
| SCHEMBL22718118 | 0.82 | POLQ (0.48) | POLQPDE5A | |
| SCHEMBL30526572 | 0.82 | POLQ (0.45) | POLQPDE5AKDM4EALDH1A1HPGD | |
| SCHEMBL25306893 | 0.82 | POLQ (0.45) | POLQPDE5AKDM4EALDH1A1HPGD | |
| SCHEMBL25213171 | 0.81 | PTGDR2 (0.43) | PDK2PDK4BDKRB1KDM4EALDH1A1 | |
| SCHEMBL30474045 | 0.81 | PTGDR2 (0.43) | PDK2PDK4BDKRB1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | BEIGENE, LTD. (KY) | 2025-01-23 | — | — | US | disclosed |
| EP-4463456-A1 | THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | BeiGene, Ltd. (KY) | 2024-11-20 | — | — | EP | disclosed |
| CN-118510778-A | Thiazolopyridylamide derivatives as inhibitors of DNA polymerase θ | 百济神州有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023134708-A1 | THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | BEIGENE , LTD. (KY) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | POLQ, POLK, POLI | POLQ 1/4885PDE5A 2870/4885ABL1 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.